Does Dupilumab work better against severe atopic dermatitis?

Hello,

Welcome to icliniq.com.

I have read your query and can understand your concern.

Severe atopic dermatitis (AD) can significantly impact the quality of life, and it is commendable that you are seeking clarity on the next steps. When conventional topical therapies fail, systemic treatments like Dupilumab or oral JAK (Janus Kinase) inhibitors are viable options.

Here is a detailed comparison and guidance:

Dupilumab (biological therapy) is an FDA (Food and Drug Administration) approved monoclonal antibody for treating moderate to severe atopic dermatitis (AD). It targets IL-4 (interleukin-4) and IL-13 (interleukin-13) pathways to reduce inflammation. It is administered as a subcutaneous injection every two weeks. The benefits are an excellent long-term safety profile. There is a significant reduction in itching, flares, and the need for steroids. No routine laboratory monitoring is required.

The risks and side effects are eye issues like conjunctivitis and dry eyes, shown in 10 to 30% of users. The rare side effects are facial redness and injection site reactions.

Vaccine safety:

It is safe to receive inactivated (killed) vaccines. Live vaccines should be avoided, although Dupilumab has minimal immune suppression compared to other systemic drugs.

The probable causes are:

1. Type 2 inflammatory pathway overactivation.

2. Chronic skin barrier dysfunction.

3. Immune dysregulation.

The laboratory tests to be done are:

1. CBC (complete blood count).

2. LFTs (liver function tests).

3. Lipid profile.

4. TB (tuberculosis) screening, if JAK (Janus kinase inhibitors) are considered.

Ophthalmology consult (if preexisting eye symptoms exist before taking Dupilumab) and dermatology referral for biologic initiation protocol.

The differential diagnosis are:

1. Chronic atopic dermatitis.

2. Allergic contact dermatitis.

3. Scabies.

4. Other pruritic dermatoses.

The probable diagnosis are:

1. Severe atopic dermatitis.

2. Refractory to topical therapies.

Treatment plan:

1. Take Dupilumab, and eye screening is needed.

2. Alternatively, oral JAK (Janus kinase) inhibitors can be begun if rapid control is needed and laboratory tests are clear.

3. Continue moisturizers and gentle cleansers, and avoid triggers.

4. Consider short-course oral steroids for bridging, if needed.

5. Try using emollients (ceramide-based moisturizers).

6. Avoid known allergens or irritants.

7. Have regular eye check-ups if using Dupilumab.

8. Have vaccinations (inactivated) before starting immunosuppressives.

Have a review at four to six weeks post-initiation for response assessment. Monitor laboratory tests every three months if on JAK (Janus kinase) inhibitors. Have long-term dermatology and mental health support.

I hope this answers your query.

Let me know if I need to assist you further.

Thank you.